Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Active not recruiting 6Recruiting 2Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 49Leukemia, Lymphocytic, Chronic, B-Cell 19Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma 12Recurrence 10Lymphoma, Mantle-Cell 9Lymphoma, Follicular 7Leukemia, Myeloid, Acute 7Waldenstrom Macroglobulinemia 6Neoplasms, Plasma Cell 6Myelodysplastic Syndromes 6Lymphoma, B-Cell, Marginal Zone 6Leukemia 6Lymphoma, T-Cell, Peripheral 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Burkitt Lymphoma 4Sezary Syndrome 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3

Interventions

Dexamethasone 2Calcium Dobesilate 2Bortezomib 2pomalidomide 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1atezolizumab 1Transplantation, Autologous 1Melphalan 1Lenalidomide 1Gene Expression Profiling 1Fatty Acids, Omega-3 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Smoldering Multiple Myeloma × Lenalidomide × Clear all
NCT05288062 2025-08-20

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Mayo Clinic

Phase 2 Terminated
17 enrolled 9 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡